Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.45% | 15.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.13% | 24.36% | |||
| Operating Income | -27.13% | -24.36% | |||
| Income Before Tax | -30.50% | -27.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.50% | -27.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.50% | -27.80% | |||
| EBIT | -27.13% | -24.36% | |||
| EBITDA | -29.42% | -23.28% | |||
| EPS Basic | -30.43% | -27.67% | |||
| Normalized Basic EPS | -30.30% | -27.80% | |||
| EPS Diluted | -30.43% | -27.67% | |||
| Normalized Diluted EPS | -30.30% | -27.80% | |||
| Average Basic Shares Outstanding | 0.05% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||